ストックスクリーナーアプリを入手
22.14
0.45%
0.10
アフターアワーズ：
22.25
0.11
+0.50%
Pfizer Inc (PFE) 最新ニュース
ACE Inhibitor Market Set to Witness Significant Growth by 2025-2032 | Pfizer Inc.,Merck & Co., Inc.,Novartis AG - openPR.com
Xylose Absorption Test Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Bristol-Myers Squibb Company - openPR.com
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock? - Nasdaq
Huntington's Disease Treatment Market to Hit $2.03 Billion by 2033, Driven by Cutting-Edge Therapies - GlobeNewswire Inc.
Lilly Soars As Study Shows Weight-Loss Pill to Pass Ozempic - Yahoo Finance
Pfizer (PFE) Laps the Stock Market: Here's Why - Yahoo Finance
Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase III - BioWorld MedTech
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Yahoo Finance
Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
GSK Zantac Appeal Gets Tough Questions From Some US Judges - Bloomberg.com
U.S. Unfractionated Heparin Market Is Booming Worldwide 2025-2032 | Pfizer, Inc., Sagent Pharmaceuticals - openPR.com
Neuroendocrine Tumor Treatment Market Is Booming Worldwide | - openPR.com
Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus
Pfizer, GSK to gain as CDC ACIP votes for RSV shots (NYSE:PFE) - Seeking Alpha
It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope - simplywall.st
Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC - insights.citeline.com
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield - Seeking Alpha
Lobbying Update: $20,000 of PFIZER INC lobbying was just disclosed - Nasdaq
Pfizer Says US CDC Panel Votes to Expand Recommendation for RSV Vaccine - marketscreener.com
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation - Seeking Alpha
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO - Business Wire
Pfizer: Tasty 7% Yield (NYSE:PFE) - Seeking Alpha
What You Need to Know Ahead of Pfizer's Earnings Release - Nasdaq
Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com
Stomach Cancer Drugs Market Witness Significant Growth by 2025-2032 | Pfizer Inc., Eli Lilly and Company - openPR.com
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed - BioSpace
Neuropathic Pain Market Detailed In New Research Report 2025 | - openPR.com
Why Pfizer Stock Topped the Market on Tuesday - Yahoo Finance
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Pfizer Halts Obesity Pill Development Amid Safety Concerns - Zacks Investment Research
Bernstein reiterates Pfizer stock with $30 target post-drug axe - Investing.com
Bernstein reiterates Pfizer stock with $30 target post-drug axe By Investing.com - Investing.com India
TD Cowen Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer (PFE) Gets a Hold from Bernstein - The Globe and Mail
BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged - Yahoo Finance
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury - El Paso Inc.
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill - Yahoo Finance
What You Need To Know Ahead Of Pfizer's Earnings Release - Barchart.com
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - MSN
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill? - Yahoo Finance
Pfizer scraps weight loss candidate after trial setback: What it means for the future of oral obesity drugs - munsifdaily.com
Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns - geneonline.com
Pfizer (PFE) Abandons Obesity Drug Trial Due to Safety Concerns - GuruFocus
Pfizer (PFE) Halts Trial of GLP-1 Pill Due to Safety Concerns - GuruFocus
Why Pfizer scrapped obesity pill development: Weight-loss drug market shares explored - financialexpress.com
Pfizer Ends Development of Its Obesity Pill - Time Magazine
Pfizer ends development of potential pill obesity treatment - CNN
Pfizer to no longer develop weight loss pill - The San Joaquin Valley Sun
Pfizer hits setback in obesity drug race as GLP-1 trial halts - Yahoo Finance
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Health Care Up on Defensive DemandHealth Care Roundup - MarketScreener
Obesity Drug Developers Rise on M&A Hopes After Pfizer Setback - Bloomberg.com
Pfizer halts development of weight loss pill after liver injury report - KFXL
Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our Valuation - Morningstar
Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg.com
Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review - Mega Doctor News
Pfizer, Inc. (PFE) Stock Forecasts - Yahoo Finance
0.67%
0.32%
大文字化:
|
ボリューム (24 時間):